Expertise in
7
conditions

Dr. Jennifer Crozier

Hematology
Baptist MD Anderson Cancer Center
1301 W Palm Ave, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
12 Years of Experience
Expertise in
7
conditions
Baptist MD Anderson Cancer Center
1301 W Palm Ave, 
Jacksonville, FL 

Overview

Jennifer Crozier is a Hematologist in Jacksonville, Florida. Dr. Crozier has been practicing medicine for over 12 years is highly rated in 7 conditions, according to our data. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Baptist MD Anderson Cancer Center
1301 W Palm Ave, Jacksonville, FL 32254

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 9 Less Clinical Trials

20 Total Publications

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.
High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.
Journal: Journal of surgical oncology
Published: September 28, 2021
Similar Doctors
Expertise in
34
conditions
Dr. Mohamed Kharfan
Hematology
Expertise in
34
conditions
Dr. Mohamed Kharfan
Hematology

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (13.6 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mohamed Kharfan is a Hematologist in Jacksonville, Florida. Dr. Kharfan is highly rated in 34 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft.

Expertise in
13
conditions
Dr. Asher Chanan
Hematology
Expertise in
13
conditions
Dr. Asher Chanan
Hematology

Mayo Clinic Hospital In Florida

4500 San Pablo Rd S, 
Jacksonville, FL 
 (13.6 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances

Asher Chanan is a Hematologist in Jacksonville, Florida. Dr. Chanan is highly rated in 13 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
21
conditions
Dr. Vivek Roy
Hematology
Expertise in
21
conditions
Dr. Vivek Roy
Hematology

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (13.6 miles away)
904-953-7188
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vivek Roy is a Hematologist in Jacksonville, Florida. Dr. Roy has been practicing medicine for over 47 years is highly rated in 21 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Jennifer Crozier

How do I make an appointment with Dr. Jennifer Crozier?

You can book an appointment with Dr. Jennifer Crozier by calling their office at 904-202-7300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer Crozier a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer Crozier is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer Crozier specialize in?

While Dr. Jennifer Crozier is a Hematology, they have specific expertise in Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jennifer Crozier participate in research or clinical trials?

Yes. Dr. Jennifer Crozier has published 20 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Jennifer Crozier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer Crozier accept my insurance?

Dr. Jennifer Crozier accepts most major insurance plans, including Anthem BCBS and Medicare. We recommend calling the office directly at 904-202-7300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crozier's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile